Obesity Clinical Trials in Salt Lake City, Utah

9 studies are recruiting for obesity in Salt Lake City, Utah right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

   Study ASC30-302 (AURORA-2) is a Phase III, global, multicenter, randomized, double-blind, placebo-controlled study to investigate the long-term efficacy, safety, and tolerability of three maintenance doses of once-daily oral ASC30 compared with placebo in participants with obesity or overweight and…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   AURORA-2 Clinical Site, Salt Lake City, Utah

   Locations

   135 in total

   Run by

   Ascletis Pharma (China) Co., Limited

   See if you can join NCT07743450 on ClinicalTrials.gov

2. A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

   Study ASC30-301 (AURORA-1) is a Phase III, global, multicenter, randomized, double-blind, placebo-controlled study to investigate the long-term efficacy, safety, and tolerability of three maintenance doses of once-daily oral ASC30 compared with placebo in participants with obesity or overweight wit…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   AURORA-1 Clinical Site, Salt Lake City, Utah

   Locations

   122 in total

   Run by

   Ascletis Pharma (China) Co., Limited

   See if you can join NCT07743463 on ClinicalTrials.gov

3. A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

   This is randomized, double-blind, placebo-controlled study of the long-term efficacy, safety, and tolerability of multiple doses of aleniglipron in participants living with overweight or obesity and T2DM. Participants will be randomized to aleniglipron or placebo for a total of 76 weeks of treatmen…

   Stage

   Phase 3

   Ages

   18 to 79

   Site

   ACCOMPLISH-2 Research Site, Salt Lake City, Utah

   Locations

   74 in total

   Run by

   Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

   See if you can join NCT07654374 on ClinicalTrials.gov

4. Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes

   The primary objective of the study is to determine the effects of ribupatide (KAI-9531) subcutaneous (SC) injection once weekly compared to placebo on percent change in body weight.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Kailera Clinical Site, Salt Lake City, Utah

   Locations

   104 in total

   Run by

   Kailera

   See if you can join NCT07284875 on ClinicalTrials.gov

5. A Study of LY4174794 in Participants With Obesity or Overweight Who Are Otherwise Healthy

   The main purpose of this study is to understand how safe and well-tolerated LY4174794 is in participants with obesity or overweight who are otherwise healthy. Blood tests will be performed to check how much LY4174794 gets into the bloodstream and how long it takes the body to eliminate it. Particip…

   Stage

   Phase 1

   Ages

   18 to 65

   Site

   ICON Early Phase Services, LLC, Salt Lake City, Utah

   Locations

   3 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07654972 on ClinicalTrials.gov

6. A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight

   This clinical study is testing how the study medicine CagriSema helps people living with obesity, with or without type 2 diabetes (T2D), lose weight. The purpose of the study is to find out how safe and effective CagriSema is for body weight loss in these participants. Participants will receive eit…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   J.Lewis Research Inc, Salt Lake City, Utah

   Locations

   303 in total

   Run by

   Novo Nordisk A/S

   See if you can join NCT07564414 on ClinicalTrials.gov

7. Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

   This study is for older children, adolescents, and young adults with B-cell Acute Lymphoblastic Leukemia (B-ALL). Higher amounts of body fat is associated with resistance to chemotherapy in patients with B-ALL. Chemotherapy during the first month causes large gains in body fat in most people, even …

   Stage

   Phase 2

   Ages

   7 to 25

   Site

   Primary Children's Hospital, Salt Lake City, Utah

   Locations

   16 in total

   Run by

   Etan Orgel

   See if you can join NCT05082519 on ClinicalTrials.gov

8. Sit Less, Interact and Move More (SLIMM) 2 Study

   * Prolonged sitting (sedentary behavior) is a risk factor for decreased kidney function, obesity, diabetes and mortality. Prolonged sitting is associated with decreased kidney function and increased risk of diabetes, heart disease and death. * In a previous pilot study funded by NIH, it was shown t…

   Stage

   Phase 2

   Ages

   20 and older

   Site

   University of Utah, Salt Lake City, Utah

   Locations

   2 in total

   Run by

   Srinvasan Beddhu

   See if you can join NCT05173714 on ClinicalTrials.gov

9. PreventT2 Together: Examining the Efficacy of Couple-based Lifestyle Intervention to Prevent Type 2 Diabetes

   Nearly half of adults in the United States have or are at risk of developing type 2 diabetes. The overall goal of this community-engaged research is to examine the efficacy of an innovative couple-based lifestyle intervention to prevent type 2 diabetes that is applicable to a broad range of partner…

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of Utah, Salt Lake City, Utah

   Run by

   University of Utah

   See if you can join NCT06690788 on ClinicalTrials.gov